

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
-------------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
------------------------------	--

CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Sanofi-Synthelabo		11/30/2001	CORPORATION: FRANCE

RECEIVING PARTY DATA	
Name:	Fonda BV
Street Address:	Roermondsplein
City:	Arnhem
State/Country:	NETHERLANDS
Postal Code:	20-6811 JN
Entity Type:	CORPORATION: NETHERLANDS

PROPERTY NUMBERS Total: 1	
Property Type	Number
Registration Number:	2725323

CORRESPONDENCE DATA	
Fax Number:	(914)693-4236
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	914 674-5463
Email:	diane.moxley@akzonobel.com
Correspondent Name:	Joan M. McGillycuddy
Address Line 1:	7 Livingstone Avenue
Address Line 2:	Akzo Nobel Inc.-Intellectual Property
Address Line 4:	Dobbs Ferry, NEW YORK 10522

ATTORNEY DOCKET NUMBER:	18117US2
--------------------------------	----------

DOMESTIC REPRESENTATIVE	
Name:	David H. Vickrey
Address Line 1:	7 Livingstone Avenue
Address Line 2:	Akzo Nobel Inc.-Intellectual Property
Address Line 4:	Dobbs Ferry, NEW YORK 10522

CH \$40.00 2725323

NAME OF SUBMITTER:

Joan M. McGillicuddy

Total Attachments: 1

source=Fonda Assignment.tif



Roermondsplein 20, 6811 JN Arnhem, The Netherlands, Telephone +31 (0) 26 446 30 71, Fax +31 (0) 26 445 12 52

TRADEMARK ASSIGNMENT



Be it known that, effective as of November 30, 2001 :

Sanofi-Synthelabo, a French corporation located and doing business at 174 avenue de France 75013 Paris – France, duly represented by its General Counsel & Senior Vice President Legal Affairs, Jean-Pierre Kerjouan and its Director of the Trademarks Department, Maryse Philbert , hereinafter referred to as the « Assignor »,

And :

Fonda BV, "Assignee", a Netherlands corporation with registered offices at Roermondsplein, 20 – 6811 JN Arnhem – The Netherlands duly represented by its managers acting jointly, R.A.A Nieuwstad and Frédéric Ollier, hereinafter referred to as the "Assignee",.

WHEREAS, the Assignor, has adopted the following trademarks :

- **ARIXTRA** (word mark) for which it has filed an application in the United States Patent and Trademark Office, Serial N° 75/651,561 dated March 2, 1999 and registered N° 2,321,564 on February 22, 2000 in respect of "pharmaceutical products for the prevention and for treatment of cardiovascular diseases or disorders" (Int'l. Class 5);
-  for which it has filed an application in the United States Patent and Trademark Office, Serial N° 76/251,409 dated May 4, 2001 in respect of "pharmaceutical products" (Int'l. Class 5) and "medical apparatus and instruments, syringes for medical purpose" (Int'l. Class 10);
-  for which it has filed an application in the United States Patent and Trademark Office, Serial N° 76/251,411 dated May 4, 2001 in respect of "pharmaceutical products" (Int'l. Class 5) and "medical apparatus and instruments, syringes for medical purpose" (Int'l. Class 10);



The pentasaccharide fondaparinux, the first agent of a new class of anti-thrombotic selective factor Xa inhibitors was discovered and is being co-developed by Sanofi-Synthelabo and Organon for the prophylaxis and the treatment of venous and arterial thromboembolic diseases.

sanofi-synthelabo

TRADEMARK

RECORDED: 09/04/2003

Registered in The Netherlands. KvK No. 09119022

REEL: 002710 FRAME: 0223